Skip to main content
. Author manuscript; available in PMC: 2018 May 30.
Published in final edited form as: Circulation. 2017 Aug 9;136(14):1304–1314. doi: 10.1161/CIRCULATIONAHA.117.028885

Figure 3. Subgroup analysis for the primary end point of target lesion failure at 1-year follow-up.

Figure 3

Subgroup analysis for prespecified baseline characteristics is shown. The P value for qualitative interaction (treatment by subgroup) is obtained from the Gail-Simon test, which assesses the heterogeneity of the treatment effect across subgroups. ACS indicates acute coronary syndrome; CI, confidence interval; RES, ridaforolimus-eluting stent; TLF, target lesion failure; and ZES, zotarolimus-eluting stent.